{"disease":{"id":"doxorubicin-induced-cardiomyopathy","name":"Doxorubicin Induced Cardiomyopathy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"razoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razoxin","generic_name":"RAZOXANE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue."},{"drug_id":"dexrazoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinecard","generic_name":"DEXRAZOXANE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Cytoprotective Agent","quality_score":10,"revenue":null,"mechanism":"Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment."},{"drug_id":"zinecard","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zinecard","company_name":"M.D. Anderson Cancer Center","drug_phase":"phase_1","molecular_target":"DNA topoisomerase 2-beta, DNA topoisomerase 2-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06092606","title":"A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Monyan Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04461223","title":"Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR","phase":"","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06427226","title":"Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT02677714","title":"99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}